Arix Bioscience (ARIX.L) Stock Price
Arix Bioscience Price
Revenue at Arix Bioscience has contracted by 25.2% per year over the past 6 years to 112,000.00 GBP. Arix Bioscience's net margin stands at -24,620.5%, down from 2,772.9% several years earlier.
Arix Bioscience stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Arix Bioscience over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Arix Bioscience stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Arix Bioscience's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Arix Bioscience Price |
|---|
Arix Bioscience Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Arix Bioscience Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEk GBP |
|---|
| GROSS MARGIN% |
| GROSS INCOMEM GBP |
| EBITM GBP |
| EBIT MARGIN% |
| NET INCOMEB GBP |
| NET INCOME GROWTH% |
| SHARESM |
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023e | 2024e | 2025e |
|---|---|---|---|---|---|---|---|---|---|---|
| – | – | 1,000.00 | 1,000.00 | – | – | – | – | – | – | – |
| – | – | -3,000.00 | -3,000.00 | – | – | – | – | – | – | – |
| -30.00 | -30.00 | -30.00 | -30.00 | -30.00 | -30.00 | -30.00 | -30.00 | -30.00 | -30.00 | -30.00 |
| -2.00 | -9.00 | -9.00 | -10.00 | -9.00 | -7.00 | -4.00 | -5.00 | -9.00 | -15.00 | – |
| – | – | -900.00 | -1,000.00 | – | – | – | – | – | – | – |
| – | -0.01 | -0.01 | 0.04 | -0.07 | 0.13 | -0.06 | -0.03 | 23.58 | – | – |
| – | 100.00 | -12.50 | -614.29 | -291.67 | -282.61 | -148.41 | -55.74 | -87,444.44 | – | – |
| 90.12 | 90.12 | 78.73 | 128.52 | 129.95 | 142.34 | 126.95 | 124.10 | 124.10 | 124.10 | 124.10 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Arix Bioscience generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Arix Bioscience retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Arix Bioscience's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Arix Bioscience has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Arix Bioscience's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Arix Bioscience stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Arix Bioscience Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Arix Bioscience business model & stock analysis
Arix Bioscience SWOT Analysis
Strengths
Arix Bioscience PLC has several strengths that contribute to its success:
- Strong research and development capabilities enable the company to innovate and stay ahead of competitors.
- Established partnerships with leading universities and research institutions provide access to groundbreaking discoveries and cutting-edge technologies.
- Diverse portfolio of investments in biotech companies reduces potential risks and offers opportunities for growth.
- Experienced and knowledgeable management team with a proven track record in the biotech industry.
Weaknesses
Despite its strengths, Arix Bioscience PLC faces certain weaknesses that may hinder its performance:
- Dependence on external collaborations and partnerships for research and development projects increases the risk of delays or setbacks.
- Reliance on the success of its invested biotech companies exposes Arix Bioscience PLC to potential financial losses if any of those companies underperform.
- Limited geographical presence restricts market opportunities and potential customer base.
Opportunities
Arix Bioscience PLC can leverage the following opportunities to support its growth:
- Expanding global demand for innovative biotech solutions offers potential for increased revenues and market expansion.
- Emerging technologies, such as gene editing and precision medicine, present significant opportunities for Arix Bioscience PLC to invest in and benefit from.
- Growing partnerships with pharmaceutical companies provide avenues for collaborative research and development projects.
Threats
Arix Bioscience PLC faces several threats that could impact its success:
- Intense competition in the biotech industry may limit the company's market share and profitability.
- Uncertainties and regulatory challenges related to drug approval processes create potential obstacles for Arix Bioscience PLC and its invested companies.
- Economic downturns and changes in healthcare policies could affect funding and investment opportunities in the biotech sector.
Arix Bioscience Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Arix Bioscience historical P/E ratio, EBIT multiple, and P/S ratio
Arix Bioscience annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Arix Bioscience shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Arix Bioscience Earnings Estimates
| Date | EPS estimate | Revenue Estimate | Quarterly report |
|---|---|---|---|
| 8/28/2019 | 0.00GBP | 639,449.00GBP | 2019 Q2 |
| 3/28/2019 | -0.00GBP | 456,749.00GBP | 2018 Q4 |
| 7/30/2018 | 0.01GBP | 6.90 MGBP | 2018 Q2 |
| 4/23/2018 | -0.03GBP | 2.26 MGBP | 2017 Q4 |
EESG©
Eulerpool ESG Scorecard© for the Arix Bioscience stock
EEnvironment
20
Environment
SSocial
20
Social
GGovernance (Corporate Governance)
4
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
Arix Bioscience shareholder structure
| % | Name |
|---|---|
26.61012% | |
9.11348% | |
5.53012% | |
5.37200% | |
5.18936% | |
4.55090% |
Arix Bioscience Executives and Management Board
Mr. Robert Lyne
Chief Executive Officer, Director
Mr. Peregrine Moncreiffe
(72)Non-Executive Independent Chairman of the Board
Dr. Debra Barker
(61)Senior Independent Non-Executive Director
Mr. Andrew Smith
(61)Non-Executive Independent Director
Arix Bioscience Supply Chain
Arix Bioscience Supply Chain
Correlation: how closely stock prices move together
| # | Name | 1M | 3M | 6M | 1Y | 2Y | Trend |
|---|---|---|---|---|---|---|---|
| 1 | 0.64 | 0.35 | 0.50 | 0.91 | 0.74 | ||
| 2 | 0.34 | -0.59 | 0.53 | 0.79 | 0.65 | ||
| 3 | -0.18 | -0.31 | 0.75 | 0.79 | 0.30 |
| # | Name | 1M | 3M | 6M | 1Y | 2Y | Trend |
|---|---|---|---|---|---|---|---|
| 1 | 0.02 | 0.63 | 0.83 | — | — | ||
| 2 | 0 | -0.28 | -0.56 | -0.50 | -0.46 | ||
| 3 | -0.26 | 0.37 | 0.78 | 0.93 | -0.25 | ||
| 4 | -0.08 | -0.63 | -0.61 | 0.57 | 0.04 |
Frequently asked questions about Arix Bioscience
The business model of Arix Bioscience PLC revolves around identifying and investing in innovative life science companies. Arix Bioscience PLC aims to provide long-term value to its shareholders by partnering with and supporting these companies to develop and commercialize breakthrough therapies and technologies. By leveraging its experienced team and global network, Arix Bioscience PLC seeks to unlock the full potential of these companies, driving growth and delivering impactful healthcare solutions. Through strategic investments and collaborations, Arix Bioscience PLC actively contributes to the advancement of the life sciences sector, ensuring a brighter future for patients and investors alike.
Arix Bioscience stock
Arix Bioscience Peer Group
Arix Bioscience Ticker
Arix Bioscience FIGI
All fundamentals and in-depth analysis of Arix Bioscience
Our stock analysis for Arix Bioscience stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Arix Bioscience. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.